Fig 1: Plasma concentrations of G-CSF and lifetime SUD. (A) Bars are estimated marginal means and 95% CI of log10-transformed concentrations of G-CSF (pg/mL) in the control and SUD groups based on the “lifetime SUD diagnosis” as factor in ANCOVA. (*) p < 0.05 denotes a significant main effect of lifetime SUD; (B) Bars are estimated marginal means and 95% CI of log10-transformed concentrations of G-CSF (pg/mL) in the SUD subgroups based on the “type of SUD diagnosis” as factor in ANCOVA (*) p < 0.05 denotes a significant main effect of type of SUD diagnosis.
Fig 2: Plasma concentrations of G-CSF and MDD diagnosis. (A) Bars are estimated marginal means and 95% CI of log10-transformed concentrations of G-CSF (pg/mL) in the control and MDD groups based on the “MDD diagnosis” as factor in ANCOVA; (B) Bars are estimated marginal means and 95% CI of log10-transformed concentrations of G-CSF (pg/mL) in the MDD subgroups based on the “antidepressant medication use” as factor in ANCOVA.
Fig 3: Plasma concentrations of G-CSF and comorbid MDD in patients with SUD. (A) Bars are estimated marginal means and 95% CI of log10-transformed concentrations of G-CSF (pg/mL) in the control and SUD groups based on the “comorbid MDD diagnosis” as factor in ANCOVA. (**) p < 0.01 denotes a significant main effect of comorbid MDD diagnosis in patients with SUD; (B) Bars are estimated marginal means and 95% CI of log10-transformed concentrations of G-CSF (pg/mL) in the cocaine subgroup based on the “comorbid MDD diagnosis” as factor in ANCOVA. (*) p < 0.05 denotes a significant main effect of comorbid MDD diagnosis; (C) Bars are estimated marginal means and 95% CI of log10-transformed concentrations of G-CSF (pg/mL) in the alcohol subgroup based on the “comorbid MDD diagnosis” as factor in ANCOVA.
Supplier Page from Wuhan Fine Biotech Co., Ltd. for Human G-CSF(Granulocyte Colony Stimulating Factor 3) ELISA Kit